期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Development of the generic drug industry in the US after the Hatch-Waxman Act of 1984 被引量:4
1
作者 Garth Boehm Lixin Yao +1 位作者 Liang Han Qiang Zheng 《Acta Pharmaceutica Sinica B》 SCIE CAS 2013年第5期297-311,共15页
The key events in the development of the US generic drug industry after the Hatch-Waxman Act of 1984 are systematically reviewed,including the process of approval for generic drugs,bioequivalence issues including“swi... The key events in the development of the US generic drug industry after the Hatch-Waxman Act of 1984 are systematically reviewed,including the process of approval for generic drugs,bioequivalence issues including“switchability”,bioequivalence for complicated dosage forms,patent extension,generic drug safety,generic substitution and low-cost generics.The backlog in generic review,generic drug user fees,and“quality by design”for generic drugs is also discussed.The evolution of the US generic drug industry after the Hatch-Waxman Act in 1984 has afforded several lessons of great benefit to other countries wishing to establish or re-establish a domestic generic drug industry. 展开更多
关键词 Generic drugs Drug Price competition and patent Term Restoration Act Abbreviated new drug application BIOEQUIVALENCE Drug quality Generic drug substitution
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部